New biomarker may unlock better treatment for Right-Sided colon cancer
Disease control
Not yet recruiting
This study looks at whether a biomarker test (EREG/AREG) can help decide if adding a targeted drug (cetuximab) to standard chemotherapy works better for people with advanced right-sided colorectal cancer. About 280 adults with wild-type RAS tumors will be enrolled. The goal is to…
Phase: PHASE4 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated May 11, 2026 20:50 UTC